Table 3. The outcome timepoints and the mortality level of patients.
| Group | Baricitinib (n = 38) | Netakimab (n = 48) | Tocilizumab (n = 34) | SOC (n = 34) | |
|---|---|---|---|---|---|
| Outcome, % (n) | hospital discharge | 97 (37) | 100 (48) | 100 (34) | 91 (31) |
| death | 3 (1) | 0 (0) | 0 (0) | 8.8 (3) | |
| Days in hospital after starting therapy, % (n) | ≤ 4 | 2.6 (1) | 4.2 (2) | 0 (0) | 0 (0) |
| 5–7 | 28.9 (11) | 37.5 (18) | 44.1 (15) | 23.5 (8) | |
| 8–14 | 57.9 (22) | 47.9 (23) | 47.1 (16) | 70.6 (24) | |
| ≥ 15 | 10.5 (4) | 10.4 (5) | 8.8 (3) | 5.9 (2) | |
Data presented as % (n), where n = number of patients; % = percentage. Evenness of parameters distribution between groups was examined with Kruskal-Wallis and Dunn test.